Form 8-K - Current report:
SEC Accession No. 0001193125-20-257858
Filing Date
2020-09-29
Accepted
2020-09-29 16:33:59
Documents
2
Period of Report
2020-09-28
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d78879d8k.htm 8-K 20421
2 EX-3.1 d78879dex31.htm EX-3.1 27290
  Complete submission text file 0001193125-20-257858.txt   48844
Mailing Address 7318 MORTON STREET DALLAS TX 75209
Business Address 7318 MORTON STREET DALLAS TX 75209 212.551.8702
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 201209270
SIC: 2836 Biological Products, (No Diagnostic Substances)